Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You could well be right. We'll know more when they go public.
FDA clears ABT’s 15-minute test for TBI/concussion:
https://finance.yahoo.com/news/abbott-receives-fda-clearance-whole-130000849.html
Note: This is not the hand-held diagnostic ABT is developing to give TBI results from a simple finger prick (#msg-172397644).
Actually, all but two of the insider buys in #msg-174141720 were from 2017 and later. But the earlier purchases were not irrelevant—they showed LG's confidence in turning the company around.
CLF—The initial several years of LG’s tenure was devoted to cleaning up the mess created by the old management team: terminating the chromite project, shutting down the money-losing Quebec mines, selling the Australian mines before they ran out of ore, and getting out of the coal business. If LG had not been hired in 2014, CLF would almost certainly have gone bankrupt in fairly short order.
In short, you can’t properly evaluate what LG has done to enhance shareholder value by using 2014 as a starting point.
The simple answer is that Dr. Kaiser was working for OCUL less than 50% of the time. Rather than be in violation of an employment covenant, he renegotiated the contract.
Thanks—good to know!
Contracting for 100% of a supplier’s API, rather than a specified quantity, is a dangerous thing to do. It almost begs for a lawsuit from a competitor, a consortium of buyers, or the FTC.
An FDA breakthrough designation does not entitle the manufacturer to a period of marketing exclusivity, as far as I know. Maybe you are thinking of an FDA Orphan Drug designation, which confers 7 years of marketing exclusivity.
Thanks. The word, "circuit" refers to the dialysis loop, right?
TEVA sues AMRN for_alleged cornering of Vascepa API:
https://www.fiercepharma.com/pharma/teva-follows-suit-after-hikmas-2023-complaint-arguing-amarin-locked-drug-ingredient-supply
Housekeeping reminder—A link to the latest version of Mufaso's compilation on oral weight-loss drugs resides in the shaded box at the bottom of the main screen for the Biotech Values message board. (The link is immediately below the one for Biotech Buyouts/Premiums.)
CLF—To fully grasp value proposition of this stock, you have to recognize how monomaniacal the CEO, Lourenco Goncalves is at generating value for shareholders. LG owns ~$120M of CLF stock, and he has regularly purchased shares on the open market or held shares after exercising options.*
The single sentence in #msg-174061258 (in reply to jbog’s post of a disparaging WSJ piece) encapsulates my view of LG’s leadership.
*Form-4 filings:
#msg-171786873
#msg-165544918
#msg-162362326
#msg-154279025
#msg-149308747
#msg-134694391
#msg-131068048
#msg-122513056
#msg-114015543
Questions about TLPH:
Is nafamostat intended only for ICU dialysis, or for dialysis in general?
How is nafamostat superior to other anticoagulants used in dialysis?
Why is the FDA treating TLPH's nafamostat as a device rather than a drug?
TIA
Aardvark Therapeutics—(private)—has_dual-acting_small-molecule weight-loss drug_in_phase-2:
https://www.ft.com/content/e3c4130d-494d-4f69-b5fe-81833f88caed
ENTA is quietly +70% since the post I’m replying to from six months ago.
Moral: A dirt-cheap valuation can be a strong catalyst in its own right.
Please elaborate. TIA
The XLO deal is tantamount to a call option for GILD.
XLO—(+130%)—inks GILD collaboration—$43.5M up-front cash (including a $13.5M equity purchase):
https://www.businesswire.com/news/home/20240328734624/en
“poorgradstudent” is on Twitter under his real name, but he hardly ever tweets:
https://twitter.com/Ogut_Ozgur
Indeed he did: #msg-111031090.
FDA—(belatedly)—approves AKBA’s Vafseo—(vadadustat)—for_dialysis_patients—stock declines:
https://finance.yahoo.com/news/akebia-receives-fda-approval-vafseo-002600187.html
He’s a serial dealmaker. Patrick somehow managed to avoid being tarnished by his close association with Martin Shkreli.
BOLD IPOs 7.19M* shares @$16.00:
https://www.businesswire.com/news/home/20240327704934/en
That's a handy chart. I would submit, however, that bioavailability is more relevant than the chart might lead one to believe insofar as it directly or indirectly causes several of the other cited advantages and disadvantages.
Please see #msg-174128961.
VTRS Investor Day slide deck shows 2026 as “anticipated launch date” for Botox-biosimilar collaboration with RVNC:
https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f (slide #14)
If this pans out it will generate material cash flow for RVNC in the next couple of years. The collaboration has $70M of remaining clinical and regulatory milestone payments. The collaboration also has up to $225M of sales-based milestones, although these presumably won’t be triggered until later in the decade.
IBIO—A second company issued a PR today mentioning both AI and obesity drugs—and it was good for a +192% move:
https://finance.yahoo.com/news/ibio-astralbio-announce-transformative-ai-110000784.html
Caveat emptor, LOL.
Loosely similar PR from 2020: #msg-155310524.
The impetus for the VTRS-RVNC Botox-biosimilar program is that the manufacturing of Daxxify generates a complexed 750-kD Botox-biosimilar compound as an intermediate step.
AVTX is +250% in AH trading. The outgoing CEO of AlmataBio (the private company AVTX is acquiring) is Patrick Crutcher, who used to be a co-moderator of this message board.
This deal is structured as a regular-way merger, but it’s conceptually a reverse-merger insofar as AVTX’s lead asset is the one they just licked up from AlmataBio.